All In MedTech

Device Trial Radar · NCT06790472

Metabolic Wellness and CGM

Assessing the Glycemic Impact of an Online Lifestyle Intervention Using CGM (Continuous Glucose Monitoring). a Pilot Study.

Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 5, 2024

Primary completion

Jun 30, 2025

Study completion Oct 11, 2025

Sponsor

Lead sponsor
David KerrAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
William Marsh Rice University; Abbott Diabetes Care
First posted
Jan 24, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the impact of participating in an online lifestyle intervention program on glycemic control as measured by Continuous Glucose Monitoring (CGM), with the primary outcome being the time-in-range (TIR) between 70 and 140 mg/dl comparing before the intervention, at the start of the program (week 1), and after the intervention (week 8).

Conditions

  • Cardiometabolic Risk Factors

Interventions

  • Online Lifestyle InterventionBehavioral

    The Metabolic Wellness Program (MWP) is an established 8-week program that provides participants with health education videos and webinars that focus on evidence-based nutrition, fitness, sleep, and stress intervention, including with CGM, allowing participants to monitor their real-time glucose data and to learn which lifestyle choices are best for their glycemic control and personal metabolic health. The program is also intended to help healthy participants maintain their metabolic health and lower their potential risk of developing cardiometabolic disease, as well as at-risk and pre-diabetic participants preventing the progression to T2D and people with established T2D reverse their condition.

  • Continuous Glucose MonitoringDevice

    CGM measurements begin at enrollment with training provided digitally Participants will be asked to "live life as usual" whilst wearing the device with initial 10-14 day readings providing baseline data. Participants will participate in the online lifestyle program, which the investigators refer to as the "intervention stage." Participants will also receive questionnaires on behavior change at the beginning of week 5. During the final two weeks of the program (weeks 7-8), the final 10-14 days of CGM will be used as comparison data with baseline information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glycemic Control (Time-in-Range)Time frame: Baseline and Weeks 2, 7-8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Palo Alto Medical Foundation

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.